Nurix Therapeutics, Inc.
About Nurix Therapeutics, Inc.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $84.0M
- Net income
- -$264.5M
- Total assets
- $688.1M
- Market cap
- $1.5B
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Balance sheet
- Total assets
- $636.1M
- Current assets
- $554.4M
- Total liabilities
- $155.2M
- Current liabilities
- $92.2M
- Shareholders’ equity
- $480.9M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $1.5B
- Shares outstanding
- 96.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 24, 2020
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $264.5M in FY2025.
- Revenue grew 182% from FY2021 to FY2025.
- Trading 27% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Nurix Therapeutics, Inc..
Write a review
News about Nurix Therapeutics, Inc.
News & sentiment via Polygon.io
